ALPK3-Related Hypertrophic Cardiomyopathy: Comprehensive Disease Report

Summary

ALPK3-related hypertrophic cardiomyopathy (HCM) is a Mendelian sarcomeric/M-band cardiomyopathy caused by loss-of-function (LoF) variants in ALPK3 (alpha-protein kinase 3), located at chromosome 15q25.3 (HGNC:17870; NCBI Gene 57538; OMIM gene 617608; disease MIM 618052, CMH27). ALPK3 encodes a catalytically-dead atypical α-kinase that functions as a structural M-band scaffold of the cardiac sarcomere, anchoring myomesins (MYOM1/2), MuRF (muscle ring-finger) E3 ubiquitin ligases, and the autophagy adaptor SQSTM1/p62 to maintain thick-filament proteostasis. It is a distinctive disease because it exhibits a dose-dependent, zygosity-driven severity gradient: biallelic (recessive) LoF causes a severe, often lethal prenatal/pediatric cardiomyopathy with syndromic extracardiac features, whereas heterozygous (dominant) protein-truncating variants (ALPK3tv) cause an incompletely penetrant adult-onset HCM that accounts for roughly 1–4% of adult HCM.

The core mechanism is now well supported: ALPK3 loss displaces myomesins from the M-band, driving thick-filament protein aggregation, sarcomere and intercalated-disc disarray, abnormal calcium handling, and hypercontractility. In model systems, these defects were partially corrected by the myosin inhibitor mavacamten, and durable phenotypic rescue was achieved in global knockout mice using AAV-delivered ALPK3, establishing two genotype-directed therapeutic proof-of-concept fronts that remain preclinical. Clinically, the adult heterozygous phenotype has a characteristic morphology — apical/septal hypertrophy, apical aneurysm, right-ventricular involvement, and myocardial fibrosis — and ALPK3 has emerged as one of the leading (frequently the second most common) genotypes identified in apical HCM cohorts.

Management currently follows standard HCM guidelines (beta-blockers, disopyramide, septal reduction therapy, ICD for sudden-cardiac-death [SCD] prevention, and transplantation for end-stage disease), with cardiac MRI late gadolinium enhancement (LGE) serving as a key risk-stratification marker particularly relevant to the fibrosis- and aneurysm-prone ALPK3 phenotype. ALPK3 now carries established gene–disease validity for HCM with recognized dual (recessive and dominant) inheritance per the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel.

1. Disease Information

Overview. ALPK3-related cardiomyopathy is an inherited cardiac muscle disease presenting predominantly as hypertrophic cardiomyopathy, but with a broad phenotypic spectrum that also includes dilated cardiomyopathy (DCM), a neonatal DCM-to-hypertrophy transition, and restrictive/mixed physiology. The disease exists as a spectrum defined by zygosity: severe recessive pediatric disease at one pole and penetrance-limited adult dominant HCM at the other.

Key identifiers.

Synonyms / alternative names: ALPK3 cardiomyopathy; ALPK3-related HCM; CMH27; alpha-kinase 3 cardiomyopathy; biallelic ALPK3 pediatric cardiomyopathy (recessive form); ALPK3tv HCM (heterozygous truncating-variant form).

Information source. Evidence is derived from aggregated disease-level and patient-level literature — systematic variant curations, multicentric cohorts (French, Swedish, Chinese), individual case reports, and functional model-organism/iPSC studies — rather than from a single EHR dataset.

2. Etiology

Primary causal factor: genetic. ALPK3-related cardiomyopathy is a monogenic disorder caused by loss-of-function variants in ALPK3. There is no established environmental or infectious cause. The disease displays a dose-dependent relationship between ALPK3 gene dosage and phenotype severity (Finding F001; Finding F007).

Genetic risk factors. - Biallelic LoF variants (homozygous or compound heterozygous nonsense, frameshift, or splice variants) → severe, often lethal, prenatal/early-onset cardiomyopathy with extracardiac involvement (recessive). - Heterozygous protein-truncating variants (nonsense/frameshift/splice) → adult-onset dominant HCM explaining ≈1–4% of adult HCM. - As stated in the integrative review (PMID: 41221624): "Biallelic loss-of-function variants lead to severe, often lethal cardiomyopathy with prenatal or early onset presentation and extracardiac involvement. Heterozygous protein-truncating variants, defined as nonsense or frameshift (resulting from insertion/deletion events or splicing mutations), explain ≈1% to 4% of adult hypertrophic cardiomyopathy."

Environmental / demographic risk factors. No specific toxic, occupational, or infectious triggers are established. Male predominance is reported among heterozygous ALPK3tv HCM patients, and age is a strong modifier given the late onset and age-dependent penetrance (PMID: 41645375). Consanguinity is an important contextual factor for the recessive form — the founding families were consanguineous (PMID: 26846950).

Protective factors. No specific genetic or environmental protective alleles are established for ALPK3 cardiomyopathy. The incomplete penetrance of heterozygous variants (~20% in the founding family; even lower in later cohorts) implies the existence of unidentified genetic/environmental modifiers that buffer disease expression.

Gene–environment interactions. Not specifically characterized. The variable expressivity within families carrying identical variants (e.g., a mother with severe obstructive HCM and an asymptomatic brother carrying the same variant; PMID: 41645375) points to modifier effects, but specific gene–environment interactions have not been mapped.

3. Phenotypes

ALPK3 cardiomyopathy has distinct cardiac and extracardiac phenotype clusters, with the extracardiac cluster largely confined to the biallelic (recessive) pediatric form.

Cardiac phenotypes

Extracardiac phenotypes (biallelic/recessive form — syndromic)

Onset, severity, progression: Biallelic disease is neonatal/prenatal-onset, severe, and often lethal (progressive; frequent early death). Heterozygous disease is adult-onset (delayed ~10 years vs. sarcomeric HCM), variable severity, slowly progressive with age-dependent penetrance. Quality-of-life impact ranges from catastrophic (perinatal heart failure, death, transplantation in the biallelic form) to variable in adults (exertional symptoms, arrhythmia burden, ICD, and SCD risk).

4. Genetic / Molecular Information

Causal gene. ALPK3 (HGNC:17870; NCBI Gene 57538; OMIM 617608), 15q25.3. Encodes alpha-protein kinase 3, an atypical α-kinase that is catalytically dead and functions structurally.

Pathogenic variant spectrum. The disease is driven overwhelmingly by truncating / loss-of-function variants: - Nonsense (e.g., p.Arg1173, p.Ser653) - Frameshift (e.g., c.1531_1532delAA p.Lys511Argfs12; c.109del p.R37Gfs72; c.2757dup p.T920Hfs14; c.3272del p.G1091Vfs43; c.1550dupC p.Pro518ThrfsTer53) - Splice-site variants - Contiguous gene deletion of 15q25.2q25.3 has been reported in a biallelic context (37671554) - Some missense variants (e.g., p.Arg1164Gln) appear in overlap/adult phenotypes (36660067)

Documented patient-level variants exceed 150 in systematic curation (156 variants; Finding F001).

Variant classification (ACMG/AMP). Truncating variants are generally classified Pathogenic / Likely Pathogenic; classification for heterozygotes was historically complicated because ALPK3 was initially annotated as autosomal recessive — re-analysis after dominant inheritance was established upgraded several variants (41645375). Bayesian/segregation evidence has supported Likely Pathogenic calls for recurrent truncating variants.

Allele frequency. Heterozygous ALPK3 truncating variants are rare but present in population databases (gnomAD); their appreciable heterozygous frequency combined with incomplete penetrance underlies the ~1–4% contribution to adult HCM.

Somatic vs. germline. All disease-associated variants are germline. No somatic mechanism is implicated.

Functional consequence. Loss of function (haploinsufficiency in heterozygotes; complete loss in biallelic patients) — loss of the M-band scaffolding function of ALPK3.

Modifier genes / epigenetics. No specific Mendelian modifier genes are established. Notably, microRNA-384-5p regulates the ALPK3 pathway in hypertrophy models (Finding F009): "miR-384-5p was notably decreased in cardiac hypertrophic tissues and cells, and overexpression of miR-384-5p could ameliorate pressure overload" (PMID: 35510648). This provides an epigenetic/post-transcriptional regulatory axis. Chromosomal abnormalities are limited to the reported 15q25 contiguous deletion.

5. Environmental Information

ALPK3 cardiomyopathy is a monogenic disease with no established environmental, lifestyle, or infectious etiology. No toxins, radiation, pollutants, dietary factors, or pathogens are implicated as causes or triggers. As with HCM generally, strenuous competitive exercise may modulate SCD risk and symptom burden, and standard HCM lifestyle counseling applies, but these are not ALPK3-specific causal factors. Age and male sex act as demographic modifiers of penetrance in the heterozygous form (see Section 2).

6. Mechanism / Pathophysiology

Ordered causal chain

1. Loss-of-function variant in ALPK3 (biallelic → complete loss; heterozygous → haploinsufficiency) leads to reduced/absent functional ALPK3 protein at the sarcomeric M-band.
2. Loss of ALPK3 results in failure of its scaffolding function — it can no longer anchor myomesins (MYOM1/2), MuRF E3 ubiquitin ligases, and SQSTM1/p62 at the M-band.
3. Displacement of myomesins and loss of the proteostasis hub leads to impaired thick-filament protein turnover and thick-filament protein aggregation.
4. Aggregation and scaffold failure result in disordered sarcomeres and intercalated discs (ultrastructural disarray).
5. Sarcomere disarray leads to abnormal calcium handling (elevated diastolic calcium) and altered myosin mechanochemistry — a reduced super-relaxed (SRX) myosin fraction, prolonged relaxation, and hypercontractility (demonstrated in the K201X knock-in mouse).
6. Reduced PKA phosphorylation of cardiac troponin I and impaired relaxation result in diastolic dysfunction and contractile impairment.
7. Chronic contractile/proteostatic stress leads to myocyte hypertrophy, myocardial fibrosis, and (in neonates) a dilated-to-hypertrophic transition → clinical HCM/DCM, apical aneurysm, arrhythmia, heart failure, and SCD risk.

Branch: In the neonatal biallelic context, the initial manifestation is often dilated cardiomyopathy that subsequently transitions to hypertrophy — a developmentally distinct branch, consistent with ALPK3's essential role in early cardiomyocyte differentiation (PMID: 26846950; PMID: 32480058).

Inferred vs. demonstrated: Steps 2–5 are directly demonstrated in iPSC-CM/ESC-CM models and mouse knock-ins (27106955 40128237 40135575). The downstream fibrosis/arrhythmia/SCD steps (step 7) are inferred from clinical cohorts and general HCM pathophysiology.

Supporting detail

Molecular pathways & protein dysfunction. ALPK3 is a catalytically-dead M-band scaffold (Finding F002): "ALPK3 lacks catalytic activity and maintains sarcomeric proteostasis by scaffolding MYOMs (myomesins), MuRF (muscle ring-finger protein) E3 ligases, and SQSTM1 (sequestosome-1)/p62. Loss of this scaffolding function displaces MYOMs, drives thick-filament protein aggregation, and precipitates severe contractile dysfunction" (PMID: 41221624). The relevant pathway is sarcomere/myofilament assembly and the ubiquitin–proteasome/autophagy quality-control system (MuRF ligases, p62). The founding study additionally described ALPK3 as a nuclear kinase essential for early cardiomyocyte differentiation (PMID: 26846950), and the α-kinase-3 mouse work supports a scaffold model recruiting machinery for thick-filament protein turnover (PMID: 40135575).

Cellular processes. Disrupted sarcomeric proteostasis, autophagy/protein turnover, and calcium homeostasis in cardiomyocytes. Ultrastructural evidence: "Ultra-structural analysis of cardiomyocytes derived from patient-specific and human ESC-derived stem cell lines lacking ALPK3 revealed disordered sarcomeres and intercalated discs" (PMID: 27106955).

Metabolic/biochemical abnormalities. Reduced SRX myosin fraction (an energy-conserving myosin state), elevated diastolic calcium, and reduced PKA-mediated troponin I phosphorylation — collectively producing hypercontractility and impaired relaxation (PMID: 40128237).

Tissue damage. Chronic myofibrillar stress → myocardial fibrosis (prominent LGE), apical aneurysm formation, and arrhythmogenic substrate.

Suggested ontology terms. - GO biological process: sarcomere organization (GO:0045214); myofibril assembly (GO:0030239); cardiac muscle hypertrophy (GO:0003300); regulation of protein catabolic process (GO:0042176); regulation of the force of heart contraction (GO:0002026); cardiac muscle cell differentiation (GO:0055007). - GO cellular component: M band (GO:0031430); sarcomere (GO:0030017); myofibril (GO:0030016); nucleus (GO:0005634). - CL cell types: cardiac muscle cell / cardiomyocyte (CL:0000746); regular cardiac myocyte (CL:0002098).

7. Anatomical Structures Affected

Organ level. Primary organ: the heart (UBERON:0000948), specifically the cardiac ventricles — left ventricle (UBERON:0002084) with frequent apex and interventricular septum involvement, and right ventricle (UBERON:0002080) in the heterozygous form. Secondary involvement: cardiac atria (atrial fibrillation), pulmonary/systemic circulation via heart failure. Body system: cardiovascular system (UBERON:0004535). In the biallelic syndromic form, additional systems affected: musculoskeletal system (skeleton, thoracic cage), craniofacial structures (palate), and skeletal/integumentary features (short stature, joint contractures).

Tissue and cell level. Cardiac (striated) muscle tissue (UBERON:0001133); target cell = cardiomyocyte (CL:0000746). Fibrosis reflects cardiac fibroblast (CL:0002548) activation and extracellular matrix expansion.

Subcellular level. The sarcomeric M-band (GO:0031430) is the primary locus of dysfunction, with secondary involvement of the sarcomere/myofibril (GO:0030017), and nucleus (GO:0005634, reflecting ALPK3's reported nuclear localization and differentiation role).

Localization / lateralization. Cardiac involvement is biventricular/bilateral with a characteristic apical predilection in heterozygotes; hypertrophy may be asymmetric (septal) or concentric/apical.

8. Temporal Development

Onset. - Biallelic (recessive): congenital/prenatal to neonatal/early-childhood onset; acute and severe. - Heterozygous (dominant): adult-onset, insidious/chronic; onset delayed by ~10 years relative to sarcomeric-gene-positive HCM (PMID: 41645375).

Progression. - Biallelic disease is rapidly progressive; three founding-cohort patients died of heart failure within the first week of life (PMID: 26846950). A characteristic neonatal DCM → ventricular hypertrophy transition occurs in ~44% of live-born biallelic patients (PMID: 32480058). - Heterozygous disease is slowly progressive/chronic-lifelong, with left ventricular wall thickness positively correlating with age (notably in female patients).

Patterns. Disease is progressive, not relapsing-remitting; no spontaneous remission. Critical windows: the perinatal period (biallelic lethality) and adult mid-life (penetrance onset in heterozygotes) represent the key vulnerability windows and — for preclinical gene/pharmacotherapy — potential intervention windows.

9. Inheritance and Population

Inheritance — dual. ALPK3 shows both recessive (biallelic) and dominant (heterozygous truncating) disease mechanisms, now formally recognized by ClinGen (Finding F010): "Existing genes were curated for new inheritance patterns where evidence existed" (PMID: 39971408). ALPK3 carries established (definitive/strong/moderate) gene–disease validity for HCM.

Penetrance & expressivity. Heterozygous penetrance is incomplete and age-dependent — ~20% (2 of 10 heterozygous family members) in the founding family (PMID: 26846950); later cohorts suggest even lower penetrance. Expressivity is variable, with identical variants producing severe obstructive HCM in one relative and no phenotype in another (PMID: 41645375).

Epidemiology. No ALPK3-specific prevalence figure exists. Contextually, HCM affects ~1 in 500 (PMID: 39971408; PMID: 39132495), and heterozygous ALPK3tv account for ~1–4% of adult HCM, giving a rough order-of-magnitude estimate. In apical HCM specifically, ALPK3 is over-represented: 28.6% of genotype-positive apical HCM in a Swedish cohort (2nd most common after MYH7) (PMID: 40428316).

Founder effects / consanguinity. The recessive form was first identified in consanguineous families via homozygosity mapping (PMID: 26846950); consanguinity elevates biallelic risk. No specific founder variants are broadly established.

Sex ratio. Male predominance among heterozygous ALPK3tv HCM patients (PMID: 41645375).

Carrier frequency. Heterozygous truncating ALPK3 variants are present at low frequency in gnomAD; precise carrier frequencies are population-dependent.

10. Diagnostics

Imaging (cornerstone). - Echocardiography — detects ventricular hypertrophy, apical morphology, systolic/diastolic dysfunction, outflow obstruction. - Cardiac MRI (CMR) with late gadolinium enhancement (LGE) — critical for detecting apical aneurysm, RV involvement, and fibrosis burden, all characteristic of ALPK3 HCM, and central to SCD risk stratification (Finding F006). "Late gadolinium enhancement (LGE) was present in 80% of patients and LGE% independently predi[cted events]" (PMID: 41759724). Combined markers stratify risk: "Patients with LVWT ≥30 mm and LGE ≥15% had a greater risk of SCD (subdistribution hazard ratio, 5.60; 95% confidence interval, 1.90-16.5, P = .002)" (PMID: 40317285).

Electrophysiology. ECG shows left ventricular hypertrophy patterns (more prevalent in ALPK3tv than sarcomeric HCM); Holter monitoring detects AF and NSVT.

Genetic testing (definitive for etiology). - Whole-exome sequencing (WES) and whole-genome sequencing (WGS) are the primary discovery tools and identified nearly all reported variants. - HCM/cardiomyopathy gene panels should include ALPK3; historically ALPK3 was omitted or mis-annotated as recessive-only, causing missed diagnoses — periodic re-analysis/re-annotation is essential (PMID: 41645375). - Single-gene / targeted testing and cascade family testing for known variants; trio segregation (Sanger) to establish compound-heterozygous configuration in pediatric cases (PMID: 40447126). - Chromosomal microarray may be needed to detect contiguous 15q25 deletions (37671554).

Clinical criteria & differential diagnosis. Diagnosis follows standard HCM criteria (unexplained LV wall thickness ≥15 mm, or ≥13 mm with family history). Differential diagnosis includes sarcomeric HCM (MYH7, MYBPC3), infiltrative/storage cardiomyopathies (Fabry, amyloid), athlete's heart, and syndromic causes (RASopathies) — especially relevant given the extracardiac features of the biallelic form.

Screening. Cascade genetic and clinical (imaging) screening of at-risk relatives; prenatal/reproductive counseling for consanguineous families at risk of biallelic disease.

11. Outcome / Prognosis

Biallelic (recessive) form: Poor prognosis — severe, often lethal in utero, at birth, or in early childhood; heart transplantation, refractory heart failure, and cardiac arrest are reported outcomes; several founding-cohort neonates died within the first week of life (PMID: 26846950; PMID: 38356193).

Heterozygous (dominant) form: Variable, generally more favorable but with meaningful arrhythmic risk. In the apical HCM cohort where ALPK3 is prominent, 36.2% experienced HCM-related events, apical aneurysm occurred in 17.2%, AF in 41.4%, and NSVT in 29.3% (PMID: 40428316).

Prognostic factors. LV wall thickness, LGE burden/fibrosis, apical aneurysm, and NSVT are the principal risk markers for SCD. Guideline-based SCD risk algorithms have modest discriminatory power (AUC ~0.58–0.63; PMID: 39713197), and there is low inter-guideline agreement for primary-prevention ICD recommendations (Fleiss' kappa 0.340; PMID: 39557320) — reinforcing the value of CMR-LGE as an additional stratifier for the fibrosis-prone ALPK3 phenotype.

Complications. Heart failure, atrial and ventricular arrhythmias, thromboembolism (AF), apical aneurysm with thrombus, and sudden cardiac death.

12. Treatment

There is no ALPK3-specific approved therapy; management follows standard HCM guidelines, with genotype-directed therapies in preclinical development.

Pharmacotherapy (guideline HCM care; NCIT terms suggested). - Beta-adrenergic blockers (NCIT:C2496) — first-line for symptoms/obstruction. - Non-dihydropyridine calcium-channel blockers (e.g., verapamil). - Disopyramide — for obstruction. - Standard heart-failure therapy for the DCM/systolic-dysfunction phenotype. - Anticoagulation for AF.

Genotype-directed / advanced therapeutics (preclinical proof-of-concept; Finding F003). - Mavacamten (cardiac myosin inhibitor; NCIT:C171741) — "Contractile and calcium handling defects were partly corrected by treatment with mavacamten, a novel myosin inhibitor" (PMID: 40128237). Targets the hypercontractility/SRX defect central to ALPK3 pathophysiology. - AAV-based gene replacement therapy — "durable phenotypic rescue in global knockout mice using an adeno-associated virus" delivering ALPK3 (PMID: 41221624). Directly addresses the LoF mechanism. - miR-384-5p modulation — a candidate therapeutic axis based on amelioration of pressure-overload hypertrophy via the ALPK3 pathway (PMID: 35510648).

Surgical / interventional. - Septal reduction therapy — surgical septal myectomy (NCIT:C51899) or alcohol septal ablation for obstruction. - Implantable cardioverter-defibrillator (ICD) (NCIT:C50077) for primary/secondary SCD prevention, guided by CMR-LGE-informed risk stratification. - Heart transplantation (NCIT:C15328) for end-stage disease (used in severe pediatric/biallelic cases).

Supportive care. Symptom management, exercise counseling, arrhythmia management, and heart-failure supportive therapy.

13. Prevention

Primary prevention. Because ALPK3 cardiomyopathy is monogenic, primary prevention is reproductive/genetic: carrier identification, genetic counseling (especially for consanguineous couples at risk of biallelic disease), and reproductive options including preimplantation genetic testing (PGT) and prenatal diagnosis.

Secondary prevention. Cascade genetic testing and serial clinical/imaging surveillance of at-risk relatives to detect subclinical disease early — important given incomplete, age-dependent penetrance. Periodic re-analysis of previously "negative" HCM genetic tests to capture ALPK3 as knowledge of its dominant mechanism has matured (PMID: 41645375).

Tertiary prevention. Prevention of complications in diagnosed patients: ICD for SCD prevention (CMR-LGE-informed), anticoagulation for AF-related thromboembolism, heart-failure management, and activity modification.

Counseling. Genetic counseling should address dual inheritance — recessive risk in consanguineous unions and dominant, incompletely penetrant risk for offspring of heterozygotes.

No immunization or public-health/environmental prevention is applicable (non-infectious, non-environmental disease).

14. Other Species / Natural Disease

Taxonomy & orthologs. ALPK3 is highly conserved. Mouse Alpk3 (NCBI Gene 116904; Mus musculus, NCBI Taxon 10090) is the principal experimental ortholog. Human ALPK3 is NCBI Gene 57538 (Homo sapiens, NCBI Taxon 9606). The gene was originally described as Midori, a differentiation-associated cardiac gene.

Natural disease in other species. No well-characterized naturally occurring ALPK3 cardiomyopathy in companion animals or wildlife is documented in the reviewed literature (no OMIA entry established in this investigation). Disease knowledge derives from engineered rather than spontaneous animal models.

Comparative biology & conservation. The M-band scaffold function and requirement for cardiac function are evolutionarily conserved — mouse knockouts recapitulate neonatal and adult cardiac dysfunction (PMID: 40135575), supporting conserved disease mechanisms across mammals.

Transmission. Not applicable — genetic, non-zoonotic, non-transmissible.

15. Model Organisms

ALPK3 cardiomyopathy is supported by a robust set of complementary models spanning mouse and human cellular systems.

Phenotype recapitulation. Models faithfully reproduce the core cellular phenotype (sarcomere disarray, thick-filament aggregation, calcium mishandling, hypercontractility) and the age-staged cardiac dysfunction. Limitations: models less completely capture the human syndromic extracardiac features (facial/skeletal/palate anomalies) and the age-dependent incomplete penetrance of the human heterozygous form. Applications: mechanism dissection (M-band proteostasis), developmental staging of ALPK3 requirement, and preclinical testing of mavacamten and AAV gene therapy.

Mechanistic Model / Interpretation

   ALPK3 loss-of-function variant
   (biallelic = complete loss | heterozygous = haploinsufficiency)
                 |
                 v
   Loss of catalytically-dead M-band SCAFFOLD
                 |
                 v
   Failure to anchor MYOM1/2 + MuRF E3 ligases + p62/SQSTM1
                 |
                 v
   Impaired thick-filament protein turnover -> AGGREGATION
                 |
                 v
   Sarcomere + intercalated-disc DISARRAY
                 |
        +--------+---------------------------+
        v                                    v
  Ca2+ mishandling                   Reduced SRX myosin,
  (elevated diastolic Ca2+)          low PKA-cTnI phosphorylation
        |                                    |
        +----------------+-------------------+
                         v
              HYPERCONTRACTILITY + impaired relaxation
                         |
        +----------------+----------------------------+
        v (neonatal branch)                           v (adult branch)
  Dilated CM -> transition to                 Late-onset HCM: apical/septal
  hypertrophy; severe, often                  hypertrophy, apical aneurysm,
  lethal; +/- syndromic features              RV involvement, fibrosis
        |                                            |
        +----------------+---------------------------+
                         v
        Heart failure, arrhythmia (AF/NSVT), SCD risk
                         |
      Rescue points: mavacamten (hypercontractility),
                     AAV-ALPK3 (restores scaffold)

The unifying interpretation is that ALPK3 is a structural (not enzymatic) linchpin of M-band proteostasis, and disease severity scales with residual ALPK3 dosage. This single mechanism parsimoniously explains the entire clinical spectrum — from perinatal lethal recessive disease to penetrance-limited adult dominant HCM — and rationalizes two mechanistically distinct therapeutic strategies (myosin inhibition to relieve the downstream hypercontractile consequence; gene replacement to restore the upstream scaffold).

Evidence Base

Limitations and Knowledge Gaps

1. No ALPK3-specific epidemiology. Prevalence/incidence are inferred from HCM-wide figures (~1 in 500) and the ~1–4% ALPK3 contribution; no direct registry estimate exists.
2. Penetrance uncertainty. The ~20% figure derives from a single founding family; population-scale penetrance of heterozygous ALPK3tv is likely lower and imprecisely quantified. Modifier genes and gene–environment interactions remain unidentified.
3. Therapies are preclinical. Mavacamten rescue and AAV gene therapy are shown only in mouse/iPSC models; no human trials specific to ALPK3 exist. Standard HCM management is extrapolated, not ALPK3-validated.
4. Mechanistic gaps. The relative contributions of ALPK3's nuclear (differentiation) role versus its cytoplasmic M-band scaffold role are not fully resolved, and how catalytic-dead α-kinase architecture confers scaffolding specificity is incompletely defined.
5. Extracardiac pathogenesis. The mechanism linking ALPK3 loss to craniofacial/skeletal malformations in the biallelic form is unexplained.
6. Variant interpretation. Historical mis-annotation of ALPK3 as recessive-only led to under-diagnosis; many gene panels and archived tests may still under-call ALPK3.
7. Model limitations. Animal/cellular models under-represent the syndromic extracardiac phenotype and age-dependent adult penetrance.

Proposed Follow-up Experiments / Actions

1. Population penetrance study. Leverage large biobanks (e.g., the biobank gene–disease association approach of 41893039) to estimate age-specific penetrance and lifetime HCM risk for heterozygous ALPK3 truncating variants.
2. Prospective natural-history registry. Establish an ALPK3-specific longitudinal registry capturing apical aneurysm incidence, arrhythmia burden, LGE progression, and SCD to build an ALPK3-tailored risk model (given weak performance of generic guidelines).
3. Clinical translation of genotype-directed therapy. Advance AAV-ALPK3 gene replacement and evaluate mavacamten in ALPK3tv patients via biomarker-driven early-phase trials; define the therapeutic window (neonatal vs. adult).
4. Modifier discovery. GWAS/whole-genome and multi-omics analysis of penetrant vs. non-penetrant heterozygous carriers to identify genetic/epigenetic modifiers (including the miR-384-5p axis).
5. Structural biology. Determine the ALPK3 M-band interactome structure (with MYOM, MuRF, p62) via cryo-EM/AlphaFold-guided modeling to rationalize truncating-variant effects and design stabilizing therapeutics.
6. Panel/curation updates. Ensure all clinical HCM gene panels include ALPK3 with dual-inheritance interpretation, and systematically re-analyze archived "gene-negative" HCM cases.
7. Mechanism of extracardiac disease. Use conditional/humanized models to dissect the developmental basis of the syndromic facio-thoraco-skeletal features in biallelic disease.

Report compiled from 5 investigation iterations, 10 confirmed findings, and 24 reviewed papers. Evidence types: human clinical cohorts and case reports, model-organism (mouse) studies, in vitro human iPSC/ESC-cardiomyocyte studies, and expert-panel gene curation.